HDAC9 and central nervous system cancer: To assess the effect of HDAC inhibition on glioma based on IDH1/2 status, we employed six patient-derived glioma cell lines: three IDH1/2wt (0827, 0923, 0211) and three IDH1mut (0905, BT142, TB096).